SLE

Johnson & Johnson Announces Breakthrough Results: Nipocalimab SLE Phase 2 Study Demonstrates Significant Reduction in Systemic Lupus Erythematosus Activity

By Clinical Trials & Data Desk
4 June 2026

Johnson & Johnson has shared late-breaking results from its Phase 2 JASMINE trial highlighting that nipocalimab achieves a sustained reduction in systemic lupus erythematosus (SLE) disease activity through 52 weeks.

Regulatory Healthcare & Pharmaceuticals News

J&J’s Nipocalimab Receives FDA Fast Track Designation for Systemic Lupus Erythematosus

By Regulatory Intelligence Desk
4 March 2026

Johnson & Johnson announces FDA Fast Track designation for nipocalimab in systemic lupus erythematosus. The immunoselective therapy demonstrated reduction in lupus disease activity in Phase 2 JASMINE study, offering potential steroid-sparing benefits and accelerated FDA review timeline.

Tag: SLE

Johnson & Johnson Announces Breakthrough Results: Nipocalimab SLE Phase 2 Study Demonstrates Significant Reduction in Systemic Lupus Erythematosus Activity

J&J’s Nipocalimab Receives FDA Fast Track Designation for Systemic Lupus Erythematosus

Areas Covered

Discover More

Novartis Fabhalta Iptacopan FDA Approval Becomes First Complement Inhibitor to Slow Kidney Decline in Primary IgAN

LIPFENDRA FDA Approval: Merck’s Enlicitide Becomes First Oral PCSK9 Inhibitor to Lower LDL-C

GSK Nuvalent Acquisition: GSK Completes $10.6 Billion Nuvalent Acquisition, Expanding Lung Cancer Pipeline

Johnson & Johnson Q2 2026 Analysis: Company Reports $25.3 Billion in Sales, Raises Full-Year Outlook

Merck’s Erbitux BRAF V600E mCRC Regimen Gets EU Approval for First-Line Treatment

AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement